美国食品和药物管理局推迟对Indivior的SUBLOCADE®标签变更的最终审查, 没有新的截止日期. FDA delays final review of label changes for Indivior's SUBLOCADE® without a new deadline set.

Indivior制药公司报告说,林业发展局推迟对其最初为2025年2月7日设定的药物SubLOCADE(乙诺啡延长释放)注射的标签变更进行最后审查。 Pharmaceutical company Indivior reports that the FDA has delayed the final review of label changes for their drug SUBLOCADE® (buprenorphine extended-release) Injection, originally set for February 7, 2025. 尽管没有悬而未决的问题,但尚未提供审查的最新时间表。 Despite no outstanding issues, an updated timeline for the review is not yet provided. Indivior将在获得进一步更新后与他人分享这些更新。 Indivior will share further updates as they become available.